Prospective strategies for targeting HIV-1 integrase function
- PMID: 21359091
- PMCID: PMC3045043
- DOI: 10.4155/fmc.10.205
Prospective strategies for targeting HIV-1 integrase function
Abstract
Integration is a key step in the HIV-1 life cycle in which the ends of linear viral DNA are covalently joined with host chromosomal DNA. Integrase is the highly conserved and essential viral protein that performs two catalytically related reactions that ultimately lead to the insertion of the viral genome into that of the host cell. The only chemotherapeutic agents against integrase currently available for HIV-1 infected individuals are those that interrupt strand transfer, the second step of catalysis. Accordingly, this article outlines possible future strategies targeting the first catalytic step, 3' processing, as well as other nonenzymatic, yet indispensible, functions thought to be co-ordinated by integrase. Importantly, the interruption of irremediable recombination between viral and host DNAs represents the last step after viral entry at which an otherwise irreversible infection can be prevented.
Similar articles
-
The future of integrase inhibitors of HIV-1.Curr Opin Virol. 2012 Oct;2(5):580-7. doi: 10.1016/j.coviro.2012.08.005. Epub 2012 Sep 12. Curr Opin Virol. 2012. PMID: 22980926 Review.
-
HIV type 1 integrase inhibitors: from basic research to clinical implications.AIDS Rev. 2008 Jul-Sep;10(3):172-89. AIDS Rev. 2008. PMID: 18820719 Review.
-
Resistance to HIV-1 integrase inhibitors: A structural perspective.Drug Resist Updat. 2010 Aug-Oct;13(4-5):139-50. doi: 10.1016/j.drup.2010.05.001. Epub 2010 Jun 8. Drug Resist Updat. 2010. PMID: 20570551 Review.
-
HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure.Retrovirology. 2009 Feb 9;6:12. doi: 10.1186/1742-4690-6-12. Retrovirology. 2009. PMID: 19203393 Free PMC article.
-
Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31. J Virol. 2015. PMID: 25552724 Free PMC article.
Cited by
-
Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel Anti-HIV Drug Development.Front Microbiol. 2011 Oct 13;2:210. doi: 10.3389/fmicb.2011.00210. eCollection 2011. Front Microbiol. 2011. PMID: 22016749 Free PMC article.
-
First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients.Biochem Biophys Rep. 2022 Mar 29;30:101254. doi: 10.1016/j.bbrep.2022.101254. eCollection 2022 Jul. Biochem Biophys Rep. 2022. PMID: 35368742 Free PMC article.
-
Cellular cofactors of lentiviral integrase: from target validation to drug discovery.Mol Biol Int. 2012;2012:863405. doi: 10.1155/2012/863405. Epub 2012 Aug 7. Mol Biol Int. 2012. PMID: 22928108 Free PMC article.
-
Mass spectrometry-based proteomic approaches for discovery of HIV-host interactions.Future Virol. 2014;9(11):979-992. doi: 10.2217/fvl.14.86. Future Virol. 2014. PMID: 25544858 Free PMC article.
References
-
- Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646–650. - PubMed
-
- Evering TH, Markowitz M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today. 2007;43(12):865–877. - PubMed
-
- Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51(18):5843–5855. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical